Joint Infringement of a Method Claim Requires "Direct Control" of Each Step
Client Alert | 1 min read | 07.16.08
In MuniAuction, Inc. v. Thomson Corp. ( No. 2007-1485; July 14, 2008), a Federal Circuit panel vacates an award of $77 million based on a finding that the asserted claims were either obvious or not infringed.
On the question of obviousness, the only difference between the asserted independent claims and the prior art was the use of a web browser interface. Following KSR Int'l Co. v. Teleflex, Inc., 127 S. Ct. 1727 (2007), the Federal Circuit panel easily concludes that modifying the prior art to include a web browser was a predictable solution well within the capabilities of a person of ordinary skill in the art. The district court's finding of non-obviousness is therefore reversed as to the independent claims.
The Federal Circuit concludes that remaining dependent claims are not infringed, thus reversing the district court on this issue as well. Each of the dependent claims required at least two parties to perform all the steps. Joint infringement of a method claim requires one party to exercise "control or direction" over the entire claimed process, such that every step is attributable to the controlling party or "mastermind." In the case at hand, the evidence showed that the defendant, Thomson, did not direct another party to perform any steps on its behalf, and thus joint infringement was not proven. Joint infringement requires more than an awareness of another party's actions.
Contacts
Insights
Client Alert | 3 min read | 11.17.26
CMS Final OPPS Rule Will Reduce Reimbursement for 340B Drugs
On November 6, 2026, the Centers for Medicare and Medicaid Services (CMS) published its final 2027 Medicare Hospital Outpatient Perspective Payment System (OPPS) rule. The rule will reduce reimbursement for 340B drugs from average sales price (ASP) plus 6% (what Medicare generally pays for Part B outpatient drugs administered by providers) to ASP minus 28%, a 32% reduction. CMS originally proposed reducing reimbursement to ASP minus 33.4%. CMS indicated that this change will better align Medicare reimbursement with hospitals’ costs of acquiring 340B drugs.
Client Alert | 9 min read | 11.17.26
Priorities and Prospects for AI Legislation in the New Congress
Client Alert | 8 min read | 11.16.26
OCC’s AI Examiner Framework: How Banks’ AI Use Can Trigger Legal Liability and Supervisory Exposure
Client Alert | 3 min read | 11.13.26
Massachusetts Trade Secret Preliminary Injunctions: Prove the Harm, Tailor the Relief

